Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer
- PMID: 35582310
- PMCID: PMC9019160
- DOI: 10.20517/cdr.2021.05
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer
Abstract
The survival rates for women with ovarian cancer have shown scant improvement in recent years, with a 5-year survival rate of less than 40% for women diagnosed with advanced ovarian cancer. High-grade serous ovarian cancer (HGSOC) is the most lethal subtype where the majority of women develop recurrent disease and chemotherapy resistance, despite over 70%-80% of patients initially responding to platinum-based chemotherapy. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway regulates many vital processes such as cell growth, survival and metabolism. However, this pathway is frequently dysregulated in cancers including different subtypes of ovarian cancer, through amplification or somatic mutations of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), amplification of AKT isoforms, or deletion or inactivation of PTEN. Further evidence indicates a role for the PI3K/AKT/mTOR pathway in the development of chemotherapy resistance in ovarian cancer. Thus, targeting key nodes of the PI3K/AKT/mTOR pathway is a potential therapeutic prospect. In this review, we outline dysregulation of PI3K signaling in ovarian cancer, with a particular emphasis on HGSOC and platinum-resistant disease. We review pre-clinical evidence for inhibitors of the main components of the PI3K pathway and highlight past, current and upcoming trials in ovarian cancers for different inhibitors of the pathway. Whilst no inhibitors of the PI3K/AKT/mTOR pathway have thus far advanced to the clinic for the treatment of ovarian cancer, several promising compounds which have the potential to restore platinum sensitivity and improve clinical outcomes for patients are under evaluation and in various phases of clinical trials.
Keywords: Ovarian cancer; PI3K/AKT/mTOR pathway; chemotherapy resistance; high-grade serous; inhibitors; therapeutics.
© The Author(s) 2021.
Conflict of interest statement
All authors declared that there are no conflicts of interest.
Figures

Similar articles
-
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.Biochem Pharmacol. 2020 Feb;172:113729. doi: 10.1016/j.bcp.2019.113729. Epub 2019 Nov 27. Biochem Pharmacol. 2020. PMID: 31785230 Review.
-
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.Arch Gynecol Obstet. 2014 Dec;290(6):1067-78. doi: 10.1007/s00404-014-3377-3. Epub 2014 Aug 3. Arch Gynecol Obstet. 2014. PMID: 25086744 Review.
-
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.Gynecol Oncol. 2021 Nov;163(2):433-444. doi: 10.1016/j.ygyno.2021.07.008. Epub 2021 Jul 10. Gynecol Oncol. 2021. PMID: 34253390
-
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29. BJU Int. 2012. PMID: 23107319
-
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. Clin Genitourin Cancer. 2018. PMID: 29199023 Review.
Cited by
-
Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.Cells. 2024 Feb 15;13(4):345. doi: 10.3390/cells13040345. Cells. 2024. PMID: 38391958 Free PMC article. Review.
-
Capsaicin Alters the Expression of Genetic and Epigenetic Molecules In Hepatocellular Carcinoma Cell.Int J Mol Cell Med. 2022;11(3):236-243. doi: 10.22088/IJMCM.BUMS.11.3.236. Int J Mol Cell Med. 2022. PMID: 37605741 Free PMC article.
-
Therapeutic potential of Achillea millefolium L. extract on 7,12-dimethylbenz(a)anthracene (DMBA) -induced ovary cancer in Wistar rats: a biochemical, molecular and histopathological approach.Toxicol Res (Camb). 2025 Jan 8;14(1):tfae235. doi: 10.1093/toxres/tfae235. eCollection 2025 Jan. Toxicol Res (Camb). 2025. PMID: 39790360
-
Advanced Therapeutic Approaches for Metastatic Ovarian Cancer.Cancers (Basel). 2025 Feb 25;17(5):788. doi: 10.3390/cancers17050788. Cancers (Basel). 2025. PMID: 40075635 Free PMC article. Review.
-
NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells.J Cell Mol Med. 2022 Oct;26(20):5277-5291. doi: 10.1111/jcmm.17557. Epub 2022 Sep 16. J Cell Mol Med. 2022. PMID: 36114703 Free PMC article.
References
-
- UK CR. Ovarian cancer statistics. 2020. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s.... [Last accessed on 10 Dec 2020]
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous